This article is adapted from the Foundation’s magazine
Dr. Lena Rivard is an electrophysiologist andcardiology researcher at the Montreal Heart Institute. An associate professor and research scholar, she’s always been fascinated by the heart, as well as by the quest for answers.
In 2020, interest in scientific research went beyond the healthcare sector and extended to the general public. The COVID-19 pandemic gave people a new perspective on the role that research plays in our daily lives and shone a light on how it works.
“I think that the pandemic has given people a newfound respect for research, because now they better understand its role in society and its impact on our daily lives,” said Dr. Rivard.
Seeing beyond the here and now
For Dr. Rivard, the public’s growing interest in research and its prominence in the news the past few months are not only positive, but crucial. We ask questions, we gain a deeper understanding of the process, and we better appreciate the need to be able to count on the resources required over the long term to further our knowledge.
“Today, we’re finally seeing the impact of dozens of years of research into the technology behind the COVID vaccines. As a result of events like the one we’re currently living through, we realize that the work researchers do can have a real effect on people’s lives,” she noted.
In the majority of cases, the tangible benefits of research aren’t immediate. But, when a problem comes up, it’s the sum of scientific advances that allow the solution to be found quickly. “Research didn’t suddenly come into the service of society. It’s always been there,” she added.
As the principal investigator of the BRAIN-AF study, Dr. Rivard knows all too well that a scientific solution can sometimes take years to emerge.
“If all goes well, in four years, we’ll have answered the question posed in BRAIN-AF: Is there a causal link between the administration of anticoagulant therapy and the prevention of cognitive decline in young patients with atrial fibrillation?” she explained.
This is a long-term mission, the precise outcome of which is still unknown. Whether the results are conclusive or not, the efforts invested will have advanced science for the common good. And that’s what we have to bear in mind.
Are you sensitive to the needs of patients and want to support research?donate today
Dreaming of a bright futureAugust 26, 2022
A glimpse at the future of researchAugust 12, 2022
Waiting for a new heart while raising funds for the cause
You will also like:
Preventing cognitive decline caused by atrial fibrillation
Dr. Lena Rivard and her colleagues Dr. Denis Roy and Dr. Paul Khairy, physician researchers in cardiology and electrophysiologists at the Montreal Heart Institute, are leading BRAIN-AF, the world’s first study that seeks to demonstrate a link between atrial fibrillation and cognitive decline in young patients.Read more →
The COLCOT study: a world-class discovery made at the Montreal Heart Institute
Researchers at the Montreal Heart Institute launched a global study titled COLCOT (COLchicine Cardiovascular Outcomes Trial) in 2014. The goal was to determine whether colchicine, a widely available drug, could prevent the risk of heart attacks in patients who had already experienced this kind of event.Read more →
COLCOT-T2D: how can we prevent cardiovascular diseases in type 2 diabetics?
With support from the MHI Foundation’s donors, Dr. Jean-Claude Tardif was able to launch COLCOT-T2D, the second phase of the COLCOT study. The goal is to demonstrate that colchicine can also prevent cardiovascular diseases in diabetics.Read more →
Atrial fibrillation: a topic of interest at the Montreal Heart Institute
Atrial fibrillation is the most common heart rhythm disorder, affecting about 700,000 Canadians. Find out more about this cardiovascular condition that is a topic of interest for many researchers at the Montreal Heart Institute.Read more →